A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens

Almenara-Fuentes L, Rodriguez-Fernandez S, Rosell-Mases E, Kachler K, You A, Salvado M, Andreev D, Steffen U, Bang H, Bozec A, Schett G, Le Panse R, Verdaguer J, Dalmases M, Rodriguez-Vidal S, Barneda-Zahonero B, Vives-Pi M (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Nanomedicine : nanotechnology, biology, and medicine

Book Volume: 48

Article Number: 102635

DOI: 10.1016/j.nano.2022.102635

Abstract

Autoimmune diseases (AIDs) are caused by the loss of self-tolerance and destruction of tissues by the host's immune system. Several antigen-specific immunotherapies, focused on arresting the autoimmune attack, have been tested in clinical trials with discouraging results. Therefore, there is a need for innovative strategies to restore self-tolerance safely and definitively in AIDs. We previously demonstrated the therapeutic efficacy of phosphatidylserine (PS)-liposomes encapsulating autoantigens in experimental type 1 diabetes and multiple sclerosis. Here, we show that PS-liposomes can be adapted to other autoimmune diseases by simply replacing the encapsulated autoantigen. After administration, they are distributed to target organs, captured by phagocytes and interact with several immune cells, thus exerting a tolerogenic and immunoregulatory effect. Specific PS-liposomes demonstrate great preventive and therapeutic efficacy in rheumatoid arthritis and myasthenia gravis. Thus, this work highlights the therapeutic potential of a platform for several autoimmunity settings, which is specific, safe, and with long-term effects.

Authors with CRIS profile

Katerina Kachler Department of Medicine 3 – Rheumatology and Immunology Darja Andreev Department of Medicine 3 – Rheumatology and Immunology Ulrike Steffen Department of Medicine 3 – Rheumatology and Immunology Aline Bozec Juniorprofessur für Osteoimmunologie Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Ahead Therapeutics SL ES Spain (ES) Institut de Recerca Biomèdica de Lleida (IRBLleida) ES Spain (ES) Sorbonne Université FR France (FR) ORGENTEC Diagnostika GmbH DE Germany (DE)

How to cite

APA:

Almenara-Fuentes, L., Rodriguez-Fernandez, S., Rosell-Mases, E., Kachler, K., You, A., Salvado, M.,... Vives-Pi, M. (2023). A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens. Nanomedicine : nanotechnology, biology, and medicine, 48. https://dx.doi.org/10.1016/j.nano.2022.102635

MLA:

Almenara-Fuentes, Lidia, et al. "A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens." Nanomedicine : nanotechnology, biology, and medicine 48 (2023).

BibTeX: Download